Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 1Cancer Cachexia (CC) 1Cachexia 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × alkaloid GB18 × Clear all
NCT07519564 2026-04-09

A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia

Kexing Biopharm Co., Ltd.

Phase 1 Not yet recruiting
18 enrolled

Cachexia, Neoplasms

NCT07237464 2025-11-19

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants

Kexing Biopharm Co., Ltd.

Phase 1 Recruiting
36 enrolled

Cancer Cachexia (CC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡